Facial Treatment Mask Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2022

Wiseguyreports.Com Adds “Facial Treatment Mask Market: Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database

PUNE, INDIA, September 18, 2017 /EINPresswire.com/ — Global Facial Treatment Mask Industry

Latest Report on Facial Treatment Mask Market Global Analysis & 2022 Forecast Research Study

WiseGuyReports has announced the addition of a new market intelligence report to its repository titled “Global Facial Treatment Mask Market Size, Status and Forecast 2022”. The research report presents a comprehensive overview of market and growth trends of this industry in the coming years.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/2103925-global-facial-treatment-mask-market-research-report-2017

“Global Facial Treatment Mask Market" market report presents a detail qualitative analysis of the “Global Facial Treatment Mask Industry” market and its important classification and forecast for “2022". The report contains current scenario of the “Global Facial Treatment Mask Market " industry and encompasses discussion various prime factors related to markets such as growth, drive, various patterns, and control.

The report provides in depth study of “Global Facial Treatment Mask Industry” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The report identifies the strength factors of the organization that will help organizations to acquire a prominent market share, to rectify where the organization is lacking or some hole which is creating glitches for development product. Look out for more opportunities in the market, get up to date to avoid any threats, competitors and substitutes.

Top Major Key Players:

Bliss

Dr. Dennis Gross

éminence

Exuviance

Fresh

Murad

No7

Olay

Estee Lauder

Peter Thomas Roth

Philosophy

Reviva Labs

L’OREAL

The report gives the reasonable picture of current market situation which incorporates past and anticipated market data for development purpose considering reference point such as esteem and volume, innovative development, economic science and government in the market.

For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/2103925-global-facial-treatment-mask-market-research-report-2017

Some Major Points from Table of content:

Global Facial Treatment Mask Market Research Report 2017

1 Facial Treatment Mask Market Overview

2 Global Facial Treatment Mask Market Competition by Manufacturers

3 Global Facial Treatment Mask Capacity, Production, Revenue (Value) by Region (2012-2017)

4 Global Facial Treatment Mask Supply (Production), Consumption, Export, Import by Region (2012-2017)

5 Global Facial Treatment Mask Production, Revenue (Value), Price Trend by Type

6 Global Facial Treatment Mask Market Analysis by Application

7 Global Facial Treatment Mask Manufacturers Profiles/Analysis

8 Facial Treatment Mask Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

Continued…..

For more information or any query mail at sales@wiseguyreports.com

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Facilitate decision-making by analyzing historical and forecast data on solar PV module market

Solar PV Module Market Industry Report by Key Benefits, Segments, Key Players and Forecast 2020

PUNE, INDIA, September 18, 2017 /EINPresswire.com/ — Summary
"Solar PV Module Market, Update 2016 – Global Market Size, Competitive Landscape and Key Country Analysis to 2020" offers comprehensive information and understanding of the global Solar Module Market.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/928560-solar-pv-module-market-analysis-to-2020

The report offers in-depth analysis of solar PV module market at global, regional (Asia-Pacific, Americas, Europe, and Middle East and Africa) and key countries (China, India, Japan, Australia, the US, Canada, Germany, Italy, France and the UK) level. The report analyzes the solar PV module market value and volume for the historic (2010-2015) and forecast (2016-2020) period. The report covers the drivers and restraints affecting the solar PV module market, country-wise annual additions, average module price trends, and the competitive landscape for respective countries in 2015.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by team of industry experts.

Scope
The report analyses Solar PV Module market. Its scope includes –
– Analysis of the growth of solar PV module market with a focus on market value and volume in global and regional level including Asia-Pacific, Americas, Europe, and Middle East and Africa.
– The report provides solar PV module market analysis for key countries including China, India, Japan, Australia, the US, Canada, Germany, Italy, France and the UK.
– The report offers country level solar PV module market value and volume for the historical (2010-2015) and forecast (2016-2020) periods.
– It provides competitive landscape at country level for the year 2015.
– Annual additions, average module price trends, key market drivers and restraints, and analysis of their impact in solar PV module market are also discussed.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to –
– Facilitate decision-making by analyzing historical and forecast data on solar PV module market
– Develop strategies based on developments in the solar PV module market
– Identify key partners and business-development avenues, based on an understanding of the movements of the major competitors in the solar PV module market
– Respond to your competitors’ business structure, strategies and prospects

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 12
1.2 List of Figures 17
2 Introduction 22
2.1 Solar Photovoltaic Technology 22
2.2 Types of Solar Modules 22
2.2.1 Crystalline Silicon (c-Si) Modules 22
2.2.2 Thin-Film Technology 23
2.3 GlobalData Report Guidance 25
3 Solar PV Module Market, Global 26
3.1 Solar PV Module Market, Global, Overview 26
3.2 Solar PV Module Market, Global, Annual Installations, 2010-2020 27
3.2.1 Solar PV Module Market, Global, Annual Installations by Technology Type, 2010-2020 29
3.3 Solar PV Module Market, Global, Production Volume, 2010-2015 31
3.3.1 Solar PV Module Market, Global, Production Volume by Technology Type, 2010-2015 33
3.4 Solar PV Module Market, Global, Average Module Price by Technology Type, 2010-2020 35
3.5 Solar PV Module Market, Global, Market Value by Technology Type, 2010-2020 37
3.6 Solar PV Module Market, Global, Competitive Landscape 39
3.6.1 Solar PV Module Market, Global, Top Fifteen Manufacturers, 2015 39
3.6.2 Solar PV Module Market, Global, c-Si Module Market Share by Company, 2015 40
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/928560-solar-pv-module-market-analysis-to-2020

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Time Scarcity Industries Involved, Products, Drive and Forecast 2017

Global Time Scarcity Market Research Report Analysis and Forecast 2017

PUNE, INDIA, September 18, 2017 /EINPresswire.com/ — Pune, India, 18th September 2017: WiseGuyReports announced addition of new report, titled “TrendSights Analysis: Time Scarcity”.

Summary
"TrendSights Analysis: Time Scarcity" looks at meeting demand for convenient, time-saving products and services.
Demand for ease and convenience derives from being time-poor and a perception of not having enough time to do all the things that one wants or needs to do. Convenience needs pervade all aspects of life, forcing dependence on highly efficient and effective products that better facilitate busy lifestyles and maximize leisure time.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1119645-trendsights-analysis-time-scarcity

Scope
– Age of connectivity has fueled an "always on" mode among consumers seeking instant gratification from the products and services they use.
– Millennials heavily rely on time-saving products, and are most likely to work long hours and/or have a long commute compared to other cohorts.
– Fortification provides a "quick fix" way to boost nutrient levels, with 49% of consumers agreeing that food and drink is the most effective format for delivering health-enhancing ingredients.

Reasons to buy
– Gain insight into the different routes through which products can align with consumers' time scarcity – formulation, packaging,, and formats.
– Compare the presence of this trend in each industry across the FMCG space, and learn what the key opportunities are.
– Identify the innovation implications of Time Scarcity for your sector

Table of Content: Key Points
1 Trend Snapshot 6
2. What is Time Scarcity? 9
3. Why is Time Scarcity important? 18
4. Who is driving Time Scarcity? 20
5. How can Time Scarcity be capitalized on? 21
6. What Next in Time Scarcity? 28
7. Appendix 30
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1119645-trendsights-analysis-time-scarcity

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Book Presenting New Theory of Human Origins to Be Offered Free

The Kindle edition of a book that explains a new theory of evolution and human origins will be free from Amazon for five days, beginning September 19.

RICHMOND, VIRGINIA, USA, September 17, 2017 /EINPresswire.com/ — The Kindle edition of a book that explains a new theory of evolution and human origins will be free from Amazon for five days, beginning September 19.

Richmond, VA—Amazon will offer the Kindle edition free beginning September 19 and continuing through the 23rd of a new title from The Oaklea Press that draws upon research findings by the Division of Perceptual Studies at the University of Virginia Medical School to explain how Homo sapiens and individual humans alive today came to be. Entitled "Who You Are and How You Came to Be," the book’s URL on Amazon where it came be obtained at no cost on those days is:

https://www.amazon.com/dp/B074YCYVTD

Stephen Hawley Martin, the author, said, “This book turns a tenet of modern science on its head. However, based on what has been determined at UVA—that the brain does not create consciousness but in effect is a wireless receiver that captures consciousness and integrates with the body—there is no other logical explanation I can see. I challenge scientists and interested parties everywhere to read the book and to come forth with a better explanation if they can, and it won’t cost them a cent to do so.”

Martin, who can be reached through his website, went on to say that his theory explains much more than how humans evolved, including why some feel they were born the wrong sex, why child prodigies and others with amazing talents exist, and why some may suffer from irrational fears and phobias.

The Kindle edition of "Who You Are and How You Came to Be" will retail for $4.99 and the trade paperback edition, which is distributed by CreateSpace, for $9.95.

The Oaklea Press was founded in 1995 and publishes primarily business management titles, body mind & spirit, self-help, and inspirational books. Martin is the author of well over a dozen books and the winner of a number of national book awards for his work.

Steve Martin
The Oaklea Press
804-218-2394
email us here


Source: EIN Presswire

FICO Professor Howe Highlights Fair Isaac Counter-Intuitive Modeling to Right Bloomberg, NBC, and Others Wrong

SubscriberWise David Howe FICO GOAT Credit Czar

FICO GOAT and U.S. Credit Czar David Howe

Howe obtains perfect FICO scores at Equifax, Experian, and TransUnion

Howe obtains perfect Vantage Scores at Equifax, Experian, and TransUnion

SubscriberWise's David Howe, the world’s top credit scoring achiever in human history, turns to FICO to prove small-balance benefits while correcting media

Moreover, there’s not an individual on the planet that today will achieve an 850 FICO (300 to 850 FICO models) score without utilization present at the moment a FICO score is generated.”

— FICO GOAT and US Credit Czar David Howe

SAN RAFAEL, CA, UNITED STATES OF AMERICA, September 17, 2017 /EINPresswire.com/ — Watch SubscriberWise CEO and FICO grandmaster all-star triple-slam all-time greatest world champion David Howe prove media information incorrect: (YouTube) https://youtu.be/mgXOb-dq_4o

“Earlier in the year, I expanded and corrected oversimplified content from Liz Weston which appeared in publications including the LA Times, Bloomberg, and NBC,” commented David Howe, SubscriberWise founder, FICO Certified Pro, and the world’s most successful credit scoring achiever since the invention of the computer. “Specifically, the misinformation stated: ‘More than two in five (41 percent) mistakenly believed that carrying a small balance on a credit card month to month could help improve a person's credit scores’ (http://www.nbcnews.com/business/consumer/many-americans-are-still-totally-confused-about-credit-scores-n764121).

“Today I want the record to reflect that carrying a small balance, in fact, does improve a person’s credit score,” Howe emphasized.

“For the last several months I’ve been controlling specific trade accounts to demonstrate the positive impact that ‘carrying balances month to month’ actually has on the calculation of a FICO Score. And as I’ve reported – and proved in the past – there’s definitely a benefit in terms of the total number of points when obligations are indicated and credit-to-debt ratios are favorable at the very moment a FICO score is generated.

“In fact, with my particular credit profile the impact of not carrying any balances is 52 points from the max high of 850,” the FICO GOAT added. “Moreover, there’s not an individual on the planet that today will achieve an 850 FICO (300 to 850 FICO models) score without utilization present at the moment a FICO score is generated.

“I encourage anyone doubtful of the facts to view the YouTube video (https://youtu.be/mgXOb-dq_4o) ,” the Credit Czar concluded.

About SubscriberWise

SubscriberWise® launched as the first issuing consumer reporting agency exclusively for the cable industry in 2006. The company filed extensive documentation and end-user agreements to access TransUnion’s consumer database. In 2009, SubscriberWise and TransUnion announced a joint marketing agreement for the benefit of America’s cable operators (http://newsroom.transunion.com/transunion-and-subscriberwise-announce-joint-marketing-agreement). Today SubscriberWise is a risk management preferred-solutions provider for the National Cable Television Cooperative.

SubscriberWise contributions to the communications industry are quantified in the billions of dollars annually.

SubscriberWise is a U.S.A. federally registered trademark of the SubscriberWise Limited Liability Co.

Media Relations
SubscriberWise
330-880-4848 x137
email us here

FICO Utilization Explained by SubscriberWise Founder and US Credit Czar David Howe


Source: EIN Presswire

URC Ventures announces StructurePro—Model Building Structures with an iPhone leveraging Apple’s AR Kit

iPhone Building Reconstruction with StructurePro

Robust Dense Reconstruction with ARKit Pose Assisted Corrections

Typical Faulty Reconstruction Without ARKit Corrections

Image processing pipeline will empower software companies to build advanced building maintenance and inspection solutions

REDMOND, WA, UNITED STATES, September 16, 2017 /EINPresswire.com/ — StructurePro combines the rich sensor data available from Apple’s ARKit with the 3d reconstruction capabilities of the industry leading mobile phone 3d reconstruction pipeline from URC Ventures. StucturePro enables software companies to build applications that can be used by construction workers, building inspectors, or insurance claims adjusters to successfully model buildings from iPhone imagery.

Historical attempts to build similar solutions have not made it to market because of failures in 3d reconstruction algorithms to handle extreme camera rotations, textureless surfaces, and repetitive structures breaking traditional algorithms and approaches.  “After successfully launching Stockpile Reports to manage inventory using iPhones in 2012 we invested significantly in a potential solution to model residential homes and commercial buildings from 2013 to 2015”, says David Boardman CEO of URC Ventures.  We went to field trials with more than one company and even went under contract to model 4,000 buildings to help plan the allocation of maintenance budget with a large government agency.   At the end of the day we decided to pull back from the market due to usability issues training field users to successfully collection sufficient imagery to ensure complete 3d models every time”.

By integrating the advanced sensor data from AR Kit, the URC Ventures image processing pipeline is now able to successfully handle the extreme rotations introduced by average end users, textureless surfaces such as large solid color walls, and repetitive structures such as ceiling tiles.  "An untrained user taking video of an indoor scene will typically collect video with many blurry frames caused by fast camera rotations and the long image exposure times needed to handle weak indoor lighting.  These blurry frames will cause breaks in vision only 3d reconstruction pipelines.  By fusing inertial navigation based pose estimates from ARKit into our solution we create complete 3D models even in these challenging circumstances" says Dr. Brian Clipp, Chief Scientist of URC Ventures.  Another source of failure in vision-only reconstruction systems is repetitive scene structures like windows, doors or acoustic ceiling tiles.  "Using ARKit relative pose data we can eliminate many poor matches in the image pair graph and make our 3D reconstruction engine robust to repetitive features" says Dr. Jared Heinly, Sr. Researcher at URC Ventures. "Textureless surfaces like blank white walls are also a major source of failure for vision only reconstruction systems, say Dr. Charles Erignac, Sr. Researcher at URC Ventures. "Using ARKit pose constraints we can tie together a reconstruction that would otherwise break when the camera views a textureless wall."

There are other benefits beyond addressing the historical barriers to realizing solutions. Solutions now have absolute scale enabling measurements without the introduction of control points.  Performance is significantly improved by leveraging scaled motions from the accelerometer in bundle adjustment."Leveraging sensor data provides valuable reference measurements. These can significantly decrease drift in the results when fused with the vision data in the error mitigation stage of the reconstruction. This allows to estimate the volumes of objects even more accurately." says Prof. Jan-Michael Frahm, Scientific Advisor to URC Ventures.

It is now possible to have an average person with limited training walk in and around building structures to successfully model it’s structure.  “It is like magic”, says Boardman.  “Solutions that would fail or break using imagery alone are now being processed into successful building models using additional sensor data from ARKit”.  We look forward to re-investing in this use case and partnering with industry leading companies to bring solutions to market.

View the full press release

URC got its start with 2d and 3d real-time mapping for military use cases, back in the early 2000's. In 2010 they started a new company to explore commercial use cases for their technology—URC Ventures. Subsequently, they have created an immensely powerful 3d reconstruction platform utilized by companies all around the world. The company Stockpile Reports licenses the platform to power its software, measuring billions of tons of construction materials, processing millions of images each year. They've done 3d reconstruction projects for the real estate, telecommunications, video game, movie, archeology, and architecture industries.

Tony Jacobson
Stockpile Reports
4252854303
email us here

3d Building Reconstruction with StructurePro and Apple’s ARKit


Source: EIN Presswire

Fibrosis Pharmaceutical and Healthcare Pipeline Review H2


Fibrosis Assessment and Therapeutics Pipeline Review H2 2017

PUNE, INDIA, September 15, 2017 /EINPresswire.com/ — Pune, India, 15th September 2017: WiseGuyReports announced addition of new report, titled “Fibrosis – Pipeline Review, H2 2017”.

Summary
Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2258227-fibrosis-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Fibrosis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
– The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Fibrosis – Overview 7
Fibrosis – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Fibrosis – Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Fibrosis – Companies Involved in Therapeutics Development 28
Acceleron Pharma Inc 28
Aelis Farma SAS 28
Anima Biotech Ltd 28
Bristol-Myers Squibb Company 29
Cellmid Ltd 29
Clementia Pharmaceuticals Inc 30
Complexa Inc 30
Confo Therapeutics 31
EA Pharma Co Ltd 31
Five Prime Therapeutics Inc 31
Genfit SA 32
GlycoMimetics Inc 32
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2258227-fibrosis-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Dupuytren Contracture Pharmaceutical and Healthcare Pipeline Review H2

Global Dupuytren Contracture Drugs and Companies Pipeline Review H2 2017

PUNE, INDIA, September 15, 2017 /EINPresswire.com/ — Pune, India,15th September 2017: WiseGuyReports announced addition of new report, titled “Dupuytren Contracture – Pipeline Review, H2 2017”.

Summary
Dupuytren contracture is a hand deformity that usually develops slowly, over decades. Dupuytren contracture affects the connective tissue under the skin of the palm. It is a localized formation of scar tissue beneath the skin of the palm of the hand. The scarring accumulates in a tissue that normally covers the tendons that pull the fingers to grip. As Dupuytren contracture progresses, more of the fascia becomes thickened and shortened. Dimpling and puckering of the skin over the area eventually occurs. Dupuytren contracture varies in its rate of progression from minor skin puckering for many years to rapid contracture (fixed flexed position) of fingers. Dupuytren contracture can lead to an inability to fully extend the affected finger from the flexed position. This can result in a loss of normal grasping. Dupuytren contracture is seldom associated with much, if any, pain unless the affected fingers are inadvertently forcefully hyperextended. Dupuytren contracture is a fibroproliferative disorder. It involves the tissue beneath the palm of the hand that leads to finger contracture and may result in significant deformity and disability. Factors contributing to the disease include ethnicity, genetic predisposition, sex and age. Risk factors (environmental) include alcohol consumption, smoking, trauma, epilepsy and diabetes. Dupuytren contracture is usually treated by an operation to straighten the fingers followed by therapy if the angle that the fingers are bent at is large enough. Surgical treatment requires extensive postoperative therapy and there are chances that symptoms often re-occur. The molecular pathophysiology of Dupuytren contracture is complex. Extensive exploration of the molecular basis of Dupuytren contracture has led to the development of new treatment modalities such as by Clostridium histolyticum collagenase injection. There still remains a long way in the development of more promising therapies for Dupuytren contracture.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2258226-dupuytren-contracture-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Dupuytren Contracture – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dupuytren Contracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dupuytren Contracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dupuytren Contracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Dupuytren Contracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Dupuytren Contracture (Musculoskeletal Disorders).
– The pipeline guide reviews pipeline therapeutics for Dupuytren Contracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Dupuytren Contracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Dupuytren Contracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Dupuytren Contracture (Musculoskeletal Disorders)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Dupuytren Contracture (Musculoskeletal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Dupuytren Contracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Dupuytren Contracture – Overview
Dupuytren Contracture – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dupuytren Contracture – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dupuytren Contracture – Companies Involved in Therapeutics Development
MediWound Ltd
Pacira Pharmaceuticals Inc
Dupuytren Contracture – Drug Profiles
Biologic to Inhibit TNF Alpha for Dupuytrens Disease – Drug Profile
Product Description
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2258226-dupuytren-contracture-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Bone Fracture Pharmaceutical and Healthcare Pipeline Review H2

Bone Fracture Treatment Pipeline Review H2 2017

PUNE, INDIA, September 15, 2017 /EINPresswire.com/ — Summary
Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2258225-bone-fracture-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Bone Fracture – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).
– The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Bone Fracture – Overview 6
Bone Fracture – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Bone Fracture – Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2258225-bone-fracture-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Achondroplasia Pharmaceutical and Healthcare Pipeline Review H2

Global Achondroplasia Drugs and Companies Pipeline Review H2 2017

PUNE, INDIA, September 15, 2017 /EINPresswire.com/ — Pune, India, 15th September 2017: WiseGuyReports announced addition of new report, titled “Achondroplasia – Pipeline Review, H2 2017”.

Summary
Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, short arms and legs, disproportionately large head compared to the body and kyphosis. Treatment includes growth hormones.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2258224-achondroplasia-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Achondroplasia – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Achondroplasia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Achondroplasia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Achondroplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 4 respectively.

Achondroplasia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Achondroplasia (Musculoskeletal Disorders).
– The pipeline guide reviews pipeline therapeutics for Achondroplasia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Achondroplasia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Achondroplasia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Achondroplasia (Musculoskeletal Disorders)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Achondroplasia (Musculoskeletal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Achondroplasia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Achondroplasia – Overview
Achondroplasia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Achondroplasia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Achondroplasia – Companies Involved in Therapeutics Development
Ascendis Pharma A/S
BioMarin Pharmaceutical Inc
Ribomic Inc
Achondroplasia – Drug Profiles
B-701 – Drug Profile
Product Description
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2258224-achondroplasia-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire